Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Be Worth By 2029?
The market for paroxysmal nocturnal hemoglobinuria (PNH) has witnessed significant expansion lately. It is projected to escalate from $4.24 billion in 2024 to $4.67 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.1%. Factors such as increased demand for PNH treatment, growth in disposable incomes, governmental efforts, and higher healthcare spending are instrumental in the historical period’s growth.
The market size of paroxysmal nocturnal hemoglobinuria (pnh) is predicted to experience substantial growth in the coming years. The market is projected to reach a size of $6.71 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.5%. This growth during the predicted period can be accredited to factors such as the ageing population, rising demand for treatments that can be self-administered, expanded access to healthcare services, higher prevalence of comorbidities, and a growing need for personalized medical treatment. Key trends identified during this period include advancements in digital healthcare technologies, the emergence of novel and innovative treatment methodologies, the adoption of gene therapy techniques, and the focus on early intervention.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12936&type=smp
What External And Internal Drivers Are Influencing The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?
An increase in blood-related and bone marrow disorders is anticipated to fuel the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) market. Medical conditions that interfere with the composition, functionality, or production of blood or its components are termed as blood disorders. Bone marrow ailments arise when there is insufficient generation of red, white, or platelet cells in the marrow, or when the produced blood cells are defective or impaired. Being closely tied to blood and bone marrow disorders, PNH affects blood cell production, the immune system, and the bone marrow microenvironment. This rare blood affliction is connected to bone marrow failure diseases and arises when a genetic defect impacts the functions of red blood cells and platelets. For example, in August 2022, Cancer Australia, a Government agency, projected 5,202 new leukemia diagnoses in Australia for the year, with 3,198 cases in men and 2,004 in women. The chance of being diagnosed with leukemia by the age of 85 is 1 in 58 (or 1.7%), with men having a higher risk at 1 in 47 (2.1%), compared to women at 1 in 77 (1.3%). Consequently, the increasing prevalence of blood and bone marrow disorders is stimulating the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market.
What Segmentation Insights Are Provided In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Research?
The paroxysmal nocturnal hemoglobinuria (pnh)market covered in this report is segmented –
1) By Treatment Type: Medications; Bone Marrow Transplantation; Blood Transfusion; Immunosuppressive Therapy; Other Treatment Types
2) By Diagnosis Type: Flow Cytometry; High-Resolution Mass Spectrometry; Other Diagnosis Types
3) By End Use: Hospitals; Clinics; Other End Users
Subsegments:
1) By Medications: Eculizumab; Ravulizumab; Complement Inhibitors; Supportive Care Medications
2) By Bone Marrow Transplantation: Allogeneic Stem Cell Transplantation; Autologous Stem Cell transplantation
3) By Blood Transfusion: Red blood Cell Transfusion; Platelet Transfusion; Fresh Frozen Plasma Transfusion
4) By Immunosuppressive Therapy: Corticosteroids; Azathioprine; Cyclophosphamide; Mycophenolate Mofetil
5) By Other Treatment Types: Supportive Therapies; Management Of Complications
Which Trends Are Likely To Redefine Growth Paths In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?
Leading firms in the paroxysmal nocturnal hemoglobinuria (PNH) market are making strides to create unique and advanced drugs and therapies, such as injectable C5 inhibitors for PNH treatment, to maintain their market standing. An injectable C5 inhibitor is a type of monoclonal antibody that obstructs the complement component C5, mitigating inflammation and tissue harm in autoimmune diseases such as PNH. For instance, in February 2024, Chugai Pharmaceutical Co., a pharmaceutical firm based in Japan, was granted priority review approval by China’s National Medical Products Administration (NMPA) for the treatment of PNH. This distinguished China as the inaugural country to approve PIASKY, outpacing other major markets, and paving the way for entry into National Reimbursement Drug List (NRDL) negotiations in the same year. Regarded as a rare disease, PNH affects approximately 12,740 individuals in China, signifying substantial market opportunities.
Who Are The Leading Companies Driving The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?
Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc., Johnson & Johnson Pvt Ltd., F. Hoffmann-La Roche AG., Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., GE Healthcare, Regeneron Pharmaceuticals Inc., CSL Behring LLC, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Genentech Inc., Shire PLC, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., Bioverativ Inc., CinnaGen Co, BioCryst Pharmaceuticals, Omeros Corporation, Hansa Biopharma AB, Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Ltd., Akari Therapeutics PLC, RA Pharmaceuticals Inc., C5 Therapeutics Inc.
Access The Complete Report Here:
Which Geographic Regions Are Creating Strong Demand In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market?
North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2024. The regions covered in paroxysmal nocturnal hemoglobinuria (PNH) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=12936&type=smp
Browse Through More Reports Similar to the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market 2025, By The Business Research Company
Acute Myeloid Leukemia Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report
Leukemia Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report
Chronic Lymphocytic Leukemia Treatment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
